{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:44:08Z","timestamp":1770738248599,"version":"3.49.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["220762"],"award-info":[{"award-number":["220762"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SkatteFUNN","award":["224425"],"award-info":[{"award-number":["224425"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210965","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T19:54:14Z","timestamp":1548878054000},"page":"e0210965","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption"],"prefix":"10.1371","volume":"14","author":[{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Asmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"van Lunzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keikawus","family":"Arast\u00e9h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Mitsuyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozza","family":"Silvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Jolliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"\u00d6kvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Krogsgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4934-4042","authenticated-orcid":true,"given":"Maja A.","family":"Sommerfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"ref1","article-title":"Towards an HIV cure","author":"M. Churchill","year":"2011","journal-title":"Global Scientific Strategy. 1st Stakeholders consultation meeting"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","article-title":"Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial","volume":"14","author":"RB Pollard","year":"2014","journal-title":"Lancet Infectious Diseases"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2012.04.007","article-title":"Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU-Multi-HIVB, in untreated HIV-1 infected subjects","volume":"30","author":"E Vardas","year":"2012","journal-title":"Vaccine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"166ra2","DOI":"10.1126\/scitranslmed.3004682","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"F Garc\u00eda","year":"2013","journal-title":"Sci Transl Med"},{"key":"ref5","article-title":"Viral control induced by HIVCONSV vaccines and romidespin in early treated individuals.","author":"B Mothe"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12981-017-0177-4","article-title":"Eradication of HIV-1 latent reservoirs through therapeutic vaccination","volume":"14","author":"J Pankrac","year":"2017","journal-title":"AIDS Res Ther"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/COH.0000000000000444","article-title":"Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies","volume":"13","author":"N Seddiki","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral Therapy for the Prevention of HIV-1 Transmission","volume":"375","author":"MS Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy","volume":"316","author":"AJ Rodger","year":"2016","journal-title":"JAMA."},{"key":"ref11","unstructured":"Bavinton B, Grinsztejn B, Phanuphak N, Jin F, Zablotska I, Prestage G. et al. HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. 9th IAS conference 2017 23\u201326 July Paris. TUACO506LB"},{"key":"ref12","first-page":"345","article-title":"Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study","volume":"19","author":"FW Wit","year":"2005","journal-title":"AIDS"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","first-page":"13747","DOI":"10.1073\/pnas.202372199","article-title":"Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection","volume":"99","author":"A Oxenius","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","article-title":"Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals","volume":"14","author":"KE Clarridge","year":"2018","journal-title":"PLoS Pathog"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x\/rhuGM-CSF vaccination and romidepsin on the HIV-1 reservoir: a phase Ib\/IIa, single group, clinical trial","volume":"3","author":"S Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"JB Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-6405-11-33","article-title":"Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial","volume":"11","author":"A Lafeuillade","year":"2014","journal-title":"AIDS Rees. Ther"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"ofv138","DOI":"10.1093\/ofid\/ofv138","article-title":"Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction","volume":"2","author":"M Ostrowsky","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"ref19","first-page":"115","article-title":"Expert Rev Vaccines","volume":"17","author":"A Cafaro","year":"2018"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12977-018-0404-7","article-title":"Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir","volume":"15","author":"Z Wang","year":"2018","journal-title":"Retrovirology"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"CV Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1254194","article-title":"Specific HIV integration sites are linked to clonal expansion and persistence of infected cells","volume":"345","author":"F Maldarelli","year":"2014","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.1256304","article-title":"HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection","volume":"345","author":"TA Wagner","year":"2014","journal-title":"Science"},{"issue":"Suppl 2","key":"ref24","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection","volume":"214","author":"PW Hunt","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"ref25","first-page":"e1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","article-title":"Absence of detectable HIV-1 viremia after treatment cessation in an infant","volume":"369","author":"D Persaud","year":"2013","journal-title":"N Engl J Med"},{"key":"ref27","unstructured":"Violari A, Cotton M, Kuhn L, Schramm D, Paximadis M, Loubser S, et al. Viral and host characteristics of a child with perinatal HIV-1 following a prolonged period after ART cessation in the CHER trial 9th IAS conference on HIV science, 2017, 23\u201326 July, Paris, France. TUPDB0106LB."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm1520","article-title":"CD8+T-cell responses to different HIV proteins have discordant associations with viral load","volume":"13","author":"P Kiepiela","year":"2007","journal-title":"Nat. Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.vaccine.2016.01.025","article-title":"A Case for preART-Adjusted Endpoints in HIV Therapeutic Vaccine Trials","volume":"34","author":"Y Huang","year":"2016","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","article-title":"Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs","volume":"75","author":"G Tapia","year":"2017","journal-title":"J. Infect"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/infdis\/169.1.41","article-title":"Immune responses elicited by recombinant vaccina-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeat boosting","volume":"169","author":"MJ McElrath","year":"1994","journal-title":"J. Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1016\/j.vaccine.2013.07.037","article-title":"Boosters of a therapeutic HIV-1 vaccine (Vacc-4x) induce divergent polyfunctional CD8+ T cell responses related to regulatory mechanisms","volume":"31","author":"A Lind","year":"2013","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/00365548.2011.653581","article-title":"Short Communication: Intradermal Vaccination of HIV-infected Patients with Short HIV Gag p24-like Peptides Induces CD4+ and CD8+ T cell Responses Lasting more than 7 Years","volume":"44","author":"A Lind","year":"2012","journal-title":"Scand. J. Inf. Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1097\/00002030-200409240-00003","article-title":"HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).","volume":"18","author":"A-MB Kran","year":"2004","journal-title":"AIDS"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.vaccine.2005.10.012","article-title":"Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate Vacc-4x","volume":"24","author":"JN Nyhus","year":"2006","journal-title":"Vaccine"},{"key":"ref36","first-page":"2283","article-title":"Strategies for the management of antiretroviral therapy (SMART) study group","volume":"355","author":"WM El-Sadr","year":"2006","journal-title":"NEJM"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1","volume":"342","author":"TC Quinn","year":"2000","journal-title":"New Engl J Med"},{"key":"ref38","first-page":"296","article-title":"Comparable cellular immune responses in patients with and without antiretroviral treatment after immunization with HIV-1 p24, p17 and Tat consensus peptides (Vacc-5q)","volume":"5","author":"A-MB Kran","year":"2014","journal-title":"J AIDS Clin. Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/088922201750102463","article-title":"Initiation of Therapy during Primary HIV Type 1 Infection Results in a Continuous Decay of Proviral DNA and a Highly Restricted Viral Evolution","volume":"17","author":"AC Karlsson","year":"2001","journal-title":"AIDS Res. And Hum. Retroviruses"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.","volume":"11","author":"OS S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2055-6640(20)30310-1","article-title":"Highlights from the 22nd International AIDS Conference (AIDS 2018), 22\u201327 July 2018, Amsterdam, the Netherlands","volume":"4","author":"K Psomas","year":"2018","journal-title":"Journal of Virus Eradication"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"JD Siliciano","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3201\/eid2403.171797","article-title":"Ending the HIV\/AIDS Pandemic","volume":"24","author":"R Eisinger","year":"2018","journal-title":"Emerg Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T16:33:12Z","timestamp":1606321992000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210965"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210965","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}